Want to see AU:PTX full AI Analyst Report?
Top Page
Prescient Therapeutics Limited
(Sydney:PTX)
Select Model
Select Model
Rating:45Neutral
Price Target:
AU$0.07
▼(-5.71% Downside)
Action:Reiterated
Date:08/22/26
The score is held down primarily by weak financial performance, driven by ongoing losses, sustained cash burn, and the latest period’s revenue dropping to zero, which raises funding and execution risk despite low debt. Technical indicators are relatively neutral and provide only modest support. Valuation is constrained by lack of profitability (negative P/E) and no dividend yield.
Positive Factors
Low Leverage
Limited debt reduces interest and refinancing pressure, giving the company more flexibility to fund oncology development through equity, grants, or future partnerships despite its ongoing cash burn.
Negative Factors
Revenue Disappeared
Zero latest-period revenue removes current operating visibility and may indicate a lack of active commercialisation or collaboration receipts, making future funding increasingly dependent on milestones, partnerships, or capital raisings.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Limited debt reduces interest and refinancing pressure, giving the company more flexibility to fund oncology development through equity, grants, or future partnerships despite its ongoing cash burn.
Read all positive factors
Prescient Therapeutics Limited (PTX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$70.45M
Dividend YieldN/A
Average Volume (3M)690.15K
Price to Earnings (P/E)―
Beta (1Y)1.29
Revenue GrowthN/A
EPS Growth25.27%
CountryAU
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.01
Shares Outstanding1,051,514,500
10 Day Avg. Volume838,009
30 Day Avg. Volume690,151
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)4.41
Price to Sales (P/S)0.00
P/FCF Ratio-8.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Prescient Therapeutics Limited Business Overview & Revenue Model
Company Description
Prescient Therapeutics Limited (PTX.AX) is an Australian clinical-stage oncology firm dedicated to creating novel therapeutic agents for various cancer types. The company's primary experimental compound, PTX-200, is currently undergoing several cl...
How the Company Makes Money
Prescient Therapeutics is a clinical-stage biotechnology company and, based on publicly available information, it is not primarily a product-sales business. Its ability to generate revenue is typically expected to come from (i) partnering/licensin...
Prescient Therapeutics Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
60
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.11M | 0.00 | 4.36M | 3.71M | 2.43M | 1.89M |
| Gross Profit | 3.11M | -110.34K | 4.36M | 3.71M | 2.43M | 1.89M |
| EBITDA | -10.06M | -10.48M | -7.54M | -7.19M | -7.46M | -6.86M |
| Net Income | -8.86M | -7.00M | -7.32M | -8.24M | -7.00M | -5.12M |
Balance Sheet | ||||||
| Total Assets | 18.48M | 16.28M | 14.56M | 20.39M | 28.11M | 17.62M |
| Cash, Cash Equivalents and Short-Term Investments | 9.77M | 9.03M | 6.93M | 14.51M | 21.92M | 12.28M |
| Total Debt | 495.89K | 222.97K | 0.00 | 330.49K | 0.00 | 0.00 |
| Total Liabilities | 1.51M | 2.08M | 3.17M | 2.33M | 2.03M | 856.01K |
| Stockholders Equity | 16.97M | 14.20M | 11.39M | 18.07M | 26.08M | 16.76M |
Cash Flow | ||||||
| Free Cash Flow | -8.00M | -7.22M | -7.24M | -7.40M | -6.19M | -4.32M |
| Operating Cash Flow | -8.00M | -7.22M | -7.24M | -7.40M | -6.19M | -4.31M |
| Investing Cash Flow | 2.00M | 0.00 | 4.00M | 12.00M | -16.00M | -4.43K |
| Financing Cash Flow | 9.02M | 9.34M | -330.49K | 18.15K | 15.83M | 428.29K |
Prescient Therapeutics Limited Technical Analysis
Negative
0.07
Price Trends
0.08
Negative
0.07
Positive
0.07
Positive
Market Momentum
>-0.01
Positive
40.21
Neutral
23.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PTX, the sentiment is Negative. The current price of 0.07 is below the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.08, and above the 200-day MA of 0.07, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 40.21 is Neutral, neither overbought nor oversold. The STOCH value of 23.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:PTX.
Prescient Therapeutics Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | AU$5.26B | 116.06 | -1.72% | ― | 26.66% | 179.32% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$70.45M | -9.86 | -44.93% | ― | ― | 25.27% | |
45 Neutral | AU$76.63M | -0.87 | -69.20% | ― | ― | -73.11% | |
45 Neutral | AU$932.70M | -8.10 | -59.59% | ― | ― | -44.83% | |
43 Neutral | AU$43.38M | -0.65 | -93.08% | ― | 116.02% | 75.56% | |
40 Underperform | AU$36.73M | -0.31 | -134.65% | ― | ― | 62.72% |
* Healthcare Sector Average
AU:PTX
Prescient Therapeutics Limited
0.07
0.03
65.85%
AU:IMU
Imugene
0.07
-0.21
-74.64%
AU:IMM
Immutep Ltd
0.05
-0.20
-79.59%
AU:TLX
Telix Pharmaceuticals
15.58
0.63
4.21%
AU:CU6
Clarity Pharmaceuticals Ltd.
2.34
-0.84
-26.42%
AU:RAD
Radiopharm Theranostics Limited
0.01
-0.02
-62.96%
Prescient Therapeutics Limited Corporate Events
Prescient Therapeutics launches SPP briefing as it advances oncology pipeline
Aug 26, 2026
Prescient Therapeutics will host a live interactive shareholder briefing on 28 August, led by CEO James McDonnell, to discuss its current Share Purchase Plan, the intended use of proceeds, and practical details on how investors can participate. Th...
Prescient Therapeutics Launches $7m Share Purchase Plan to Advance PTX-100
Aug 25, 2026
Prescient Therapeutics has opened a Share Purchase Plan to raise up to $7 million, offering eligible shareholders new shares at $0.065, an 18.8% discount to the 10-day VWAP and a 9.7% discount to the last traded price. The move follows a year of s...
Prescient Therapeutics targets $7m via share purchase plan to fund oncology pipeline
Aug 25, 2026
Prescient Therapeutics Limited has launched a share purchase plan as part of a broader capital raising, targeting up to $7 million by offering eligible shareholders up to $30,000 of new shares at $0.065 each. The plan could result in the issuance ...
Prescient Therapeutics Launches Securities Purchase Plan for New Share Issue
Aug 25, 2026
Prescient Therapeutics Limited has announced a proposed issue of ordinary fully paid shares under a securities purchase plan to its existing shareholders. The plan allows for the issue of up to 107,692,308 new shares, with a record date of 24 Augu...
Prescient Therapeutics launches discounted $7m Share Purchase Plan to fund PTX-100 development
Aug 25, 2026
Prescient Therapeutics has launched a Share Purchase Plan to raise up to $7 million, offering new shares at $0.065 each, a discount to recent trading levels, to eligible shareholders on the register as of 24 August 2026. The funds will primarily s...
Prescient Therapeutics Files Updated ASX Corporate Governance Disclosures
Aug 20, 2026
Prescient Therapeutics Limited has lodged its annual corporate governance disclosures with the ASX, including an updated governance statement approved by the board and made available on its website in line with listing requirements. The biopharmac...
Prescient narrows annual loss as capital raisings bolster net assets
Aug 20, 2026
Prescient Therapeutics Limited reported a narrowed loss of $7.0 million for the year ended 30 June 2026, down 4.4% from the prior year, reflecting broadly stable operating costs despite higher share-based payment expenses. Corporate expenses rose ...
Prescient Therapeutics Boosts PTX-100 Trial Momentum and Expands Global Oncology Footprint
Jul 27, 2026
Prescient Therapeutics reported cash and term deposits of $9.03 million at 30 June 2026, up from $7.93 million in March, with quarterly net operating cash outflows of $2.87 million driven largely by $1.80 million in RD and clinical spending, inclu...
Prescient Therapeutics Cleans Up Capital Structure as 4 Million Options Expire
Jul 10, 2026
Prescient Therapeutics Limited has reported the cessation of a tranche of listed options, designated PTXAJ, following their scheduled expiry on 7 July 2026. The expired series comprised 4,000,000 options exercisable at $0.358, which lapsed without...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.